Pfizer Inc. announced top-line results from two phase IIIb, placebo-controlled studies with Lyrica (pregabalin) capsules CV in patients with fibromyalgia (FM) and painful diabetic peripheral neuropathy (DPN), respectively. The fibromyalgia study, A0081275 met its primary endpoint, showing a reduction in pain associated with fibromyalgia in patients who were treated concurrently with antidepressant therapy for comorbid depression. Separately, the painful DPN study, A0081269 did not meet its co-primary endpoints by sufficiently reducing DPN pain and DPN pain on walking compared to placebo.
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Loading Next Article...
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Ensuring safety in lipid nanoparticle drug delivery
As lipid nanoparticles become promising drug carriers, understanding their potential genotoxic risks is crucial.
The unsung tools behind analytical testing success
Learn how fundamental laboratory tools like pipettes and balances support analytical precision.
Improving ALS research with pluripotent stem cell-derived models
Discover new advancements in modeling amyotrophic lateral sclerosis.
